Table 2 Unadjusted hazard ratios, 95% confidence intervals and survival probabilities for 3 and 9 months (n = 1350)
Number of patients (Column %) | Unadjusted hazard ratio (95% CI) | Likelihood ratio test p-value | Kaplan-Meier probability of survival 3 months 9 months | ||
|---|---|---|---|---|---|
Gender | p = 0.49 | ||||
Male | 542 (40.2%) | 1 | 94% | 86% | |
Female | 808 (59.8%) | 0.9 (0.67, 1.21) | 94% | 87% | |
Age group (years) | p = 0.14 | ||||
18 to 29 | 325 (24%) | 1 | 95% | 91% | |
30 to 34 | 314 (23.3%) | 1.36 (86.7, 2.14) | 96% | 88% | |
35 to 39 | 288 (21.3%) | 1.77 (1.14, 2.74) | 92% | 86% | |
40 to 49 | 307 (22.7%) | 1.31 (0.83, 2.08) | 94% | 89% | |
50 to 70 | 116 (8.6%) | 1.44 (0.79, 2.63) | 94% | 86% | |
CD4 count (per μL) (n = 1257) | p < 0.0001 | ||||
0 to 49 | 473 (37.6%) | 1 | 87% | 79% | |
50 to 99 | 241 (19.2%) | 0.37 (0.23, 0.58) | 97% | 92% | |
100 to 200 | 414 (32.9%) | 0.28 (0.18, 0.42) | 98% | 94% | |
> 200 | 129 (10.3%) | 0.21 (0.10, 0.45) | 97% | 95% | |
Viral load (log 10 copies/mL) (n = 1187) | p < 0.0001 | ||||
<4 | 134 (11.3%) | 0.30 (0.15, 0.60) | 98% | 94% | |
4 to 5 | 520 (43.8%) | 0.47 (0.34, 0.66) | 97% | 92% | |
>5 | 533 (44.9%) | 1 | 90% | 82% | |
Haemoglobin (g/mL) (n = 1206)* | p < 0.0001 | ||||
<8 | 105 (8.7%) | 3.24 (2.12, 4.94) | 79% | 66% | |
8.1 - 9.9 | 207 (17.2%) | 1.94 (1.32, 2.86) | 87% | 79% | |
10 - 11.9 (12.9 for men) | 453 (37.6%) | 1 | 96% | 89% | |
>11.9 (>12.9 for men) | 441 (36.5%) | 0.38 (0.24, 0.63) | 99% | 96% | |
Body mass index (kg/m 2 ) (n = 854) | p < 0.0001 | ||||
<18.5 | 207 (24.2%) | 2.05 (1.41, 2.96) | 88% | 78% | |
18.5 to 25 | 471 (55.1%) | 1 | 95% | 88% | |
>25 | 176 (20.6%) | 0.67 (0.38, 1.16) | 99% | 93% | |
previous tuberculosis diagnosis | p = 0.12 | ||||
Yes | 314 (23.3%) | 1.3 (0.94, 1.81) | 94% | 86% | |
No | 1036 (76.7%) | 1 | 94% | 89% | |
previous tuberculosis preventive therapy | |||||
Yes | 30 (2.2%) | 0.86 (0.31, 2.35) | p = 0.77 | 93% | 93% |
No | 1320 (97.8%) | 1 | 94% | 88% | |
Treatment combination | p = 0.41 | ||||
Stavudine/lamivudine/nevirapine | 562 (41.6%) | 1 | 94% | 89% | |
Stavudine/lamivudine/efavirenz | 672 (49.8%) | 0.91 (0.67, 1.24) | 93% | 88% | |
Zidovudine/lamivudine/efavirenz | 55 (4.1%) | 1.18 (0.57, 2.47) | 98% | 87% | |
Other | 61 (4.5%) | 0.52 (0.21, 1.29) | 98% | 91% | |